University of Hull programme to support women after breast cancer
A new exercise programme will be trialled to help women return to work after experiencing breast cancer.Researcher Dr Rebecca Vince from the University of Hull was awarded £101,028 from Breast Cancer Now to set up the scheme.One in three women experience persistent tiredness after treatment, and almost half (48%) experience depression and anxiety, the university said.Dr Vince said she hoped the programme would fulfil "a very unmet need" for women after breast cancer.
An initial study will include 90 women who have had breast cancer and returned to work monitored for 12 weeks through their physical activity, fatigue, mood, pain levels and workplace performance.Researchers will then work with study participants to determine how the support can be improved and accessed.Focus groups to better understand the barriers women face and how the programme can be tailored to their needs will then be completed.The University of Hull said physical activity had be shown to "improve cancer-related fatigue" and "reduce the risk of relapse".Dr Vince said: "Quality of life is important, embodying good physical and mental health and overall well-being and happiness. "We believe our programme can address these factors and fulfil a very unmet need for women after breast cancer."
'Real potential'
Lucie Lewis, who was diagnosed with breast cancer last year, a week before her 25th birthday, said she found exercise a vital part of improving her mental health and energy for work.Ms Lewis, an audio producer who lives in Derbyshire, said: "This research is so important as I had a lot of difficulty finding any information and support around exercise after cancer in general, a lot of stuff was very focused on much older people."Dr Simon Vincent, chief scientific officer at Breast Cancer Now, said: "Almost 55,000 women are diagnosed with breast cancer each year in the UK and this number is rising. "This project has real potential to help improve women's quality of life after breast cancer treatment and also help many of them when they return to work."
Listen to highlights from Hull and East Yorkshire on BBC Sounds, watch the latest episode of Look North or tell us about a story you think we should be covering here.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
an hour ago
- The Independent
Warning over self-swab ‘rape kits' marketed to university students
Self-swab 'rape kits' are being marketed to university students in the UK, allowing individuals to collect and store DNA evidence of an alleged perpetrator. Rape Crisis England and Wales, along with forensic experts, have expressed serious concerns that evidence collected by these kits may not be legally admissible due to contamination risks and lack of comprehensive forensic examination. Critics warn that the kits could give survivors 'false hope' regarding legal outcomes, as professional forensic examinations are conducted in controlled environments and include broader evidence collection. Companies selling the kits, such as 'Enough', claim they act as a deterrent to sexual violence and offer a simpler reporting method, with some students reporting positive perceptions. Beyond legal admissibility, concerns also include the kits' inability to provide the crucial trauma-informed, in-person support that survivors need, which is offered by specialist support services.
Times
an hour ago
- Times
This defrizzing hair treatment has changed my life
I have had the most amazing hair treatment. It used to be marketed as 'Hair Botox' before actual Botox objected, but that gives you the idea. It irons out all the frizz, but without the hideous formaldehyde component of comparable treatments of yore. It is also much more effective — life-changingly so, for me. For the first time in my entire life, I can wash and go. I appreciate that most people have always been able to do this, but not me, or at least not for years. As my hair has got finer and as I have had to colour it more often, it has become a hellscape of frizz if left unattended. The treatment is called Hyrolox and comes via Ondine Cowley at Gielly Green, London (from £400, She didn't invent it — that was clever Brazilians — but she refined it and then imported it. When she suggested it might work for me, I was highly sceptical: I do not think of my hair as robust, and for this reason I try to keep well away from chemical treatments. But the idea of it being smooth was irresistible, and she kept saying she thought it would change my life — without harming my hair. On the contrary, she said it would rejuvenate it. Ondine, smooth and gorgeous of lock, has — or had — unmanageably frizzy hair herself (though you would never believe it to look at her), and I'm always encouraged by people who are brilliant adverts for their product. So I went for it, feeling slightly mad for doing so: how could it possibly work on my nightmare hair? It has changed my life, more than anything I've ever had done other than micro extensions (also at Gielly Green, courtesy of Charlie, a stone-cold genius. I wouldn't dream of seeing anybody else, anywhere. She is amazing at doing extensions for volume on thinning hair, ie me). Tragically the extensions had to come out before the Hyrolox could be applied. It goes on for however long Ondine determines, and your hair is then ironed straight but, crucially, not flat. I don't know how it's not pancake flat, but it isn't. You then have to sleep on it overnight and go back the next day. It also leaches colour out of your hair: I left the salon not only very thin of hair, but also half grey — I was having my long overdue colour and extensions redone the following day. The bit that wasn't grey was a really startling shade of pale orange. I walked from the salon to my hotel with, literally, a bag on my head, and went to dinner that night with a huge headscarf that kept slipping off. No matter: it was worth it. • Read more beauty product reviews and advice from our experts This isn't going to mean anything to many of you, but it will mean everything to those of you who have the same issue: I can wash my hair, rough dry it, and it is perfect. It is shiny, younger-feeling, with not an iota or frizz, dryness, flyawayness or anything else. It is sleek but not flat. It's the best it has looked in years. I have gone from actively avoiding washing it because it takes so long to make it look reasonable to washing it every two seconds because I can't quite believe how smooth and pliable it looks three minutes later. No product, no nothing. Not only that, but it's in the best nick it has ever been in, even though before the Hyrolox it was in the worst nick imaginable. It's the best hair treatment I've ever had and I could not recommend it more highly. I could actually weep with gratitude. Buy Nighties from If Only If, several of which are more than nice enough to wear as summer dresses (I love the brown gingham, also the lemon yellow). Before I discovered these people, nighties were a grim nightmare of faux-sexy or faux-prim. No longer! From £85, The Sunday Times Style Beauty awards are back for 2025. You could win a luxury five-star holiday at Sani Resort in Greece, plus we have more than £25,000 worth of beauty prizes up for grabs. To be entered into the prize draw, vote for your favourite products at
The Sun
an hour ago
- The Sun
Are YOU eligible for free fat jabs on the NHS? As GPs start dishing out Mounjaro – all you need to know
THEY are arguably the biggest medical breakthrough of recent times. And from Monday, so-called ' fat jab s' will be made available to many more Brits on the NHS. In what marks the dawn of a new era, GPs will begin prescribing the weight-loss jab Mounjaro in the first anti- obesity rollout of its kind. More than three million people are thought to be eligible for tirzepatide - the active drug in Mounjaro - the strongest jab on the market. Health chiefs hope it will turn the tide on England's obesity crisis which has seen rates double since the 1990s. Injections including Ozempic and Wegovy have previously only been available for type 2 diabetes or through specialist slimming clinics. Family doctors will now be encouraged to prescribe them in a bid to get more people on the meds. Experts hope widespread use will slash work sick days and boost the economy, while reducing rates of cancer, heart disease and dementia. But demand for the drugs is already huge and NHS clinics cannot dish them out fast enough. Here is everything you need to know as the rollout begins: What is Mounjaro and what has it been used for so far? 5 FOR anyone who has missed the frenzy, Mounjaro, aka tirzepatide, is the newest weight loss injection used on the NHS. It has been around since 2022 and triggers fullness hormones in the gut to prevent hunger and over-eating. This works the same as older jabs Wegovy and Ozempic, all known as GLP-1 agonists, but a recent trial showed it is more effective. A head-to-head study in the New England Journal of Medicine found Mounjaro caused 20 per cent weight loss over 18 months, while semaglutide – the active ingredient in Wegovy and Ozempic – led to 14 per cent. All the jabs were originally invented to treat type 2 diabetes but trials found they could also cause major weight loss. Pharma firms have cashed in on the discovery and UK prescriptions have skyrocketed. NHS prescriptions of Mounjaro in England surged from just 3,300 in 2023 to 1.1million last year, and more than a million people are estimated to be buying it online. Weight Loss Jabs - Pros vs Cons Who will be eligible in the new rollout? THE new rollout starting on Monday will allow GPs to prescribe tirzepatide for weight loss, starting with those patients whose weight places them at greatest health risk. Top of the list will be those with a body mass index (BMI) of 40 or higher and four weight-related health conditions. A BMI of 40 is roughly equal to weighing 16st (102kg) for an average height 5'3' woman, or 19st 6lbs (123kg) for an average 5'9' man. Weight-related conditions include high cholesterol, high blood pressure, prediabetes, type 2 diabetes, obstructive sleep apnoea and heart disease. Patients will likely be expected to have tried diet and exercise first before being offered a jab. Many are likely to miss out, as some 13.5million adults in England are obese but only 3.4million are estimated to be eligible in the rollout. How will the rollout be run and what is new? 5 WHAT'S new is that the rollout will be the first run by NHS primary care, led by GP surgeries. In theory this should make life easier for patients – but GPs will not be able to meet the huge demand. NHS bosses have admitted it will take a staggering 12 years to treat everyone who is eligible. Just 220,000 extra people are likely to get Mounjaro by 2028. Private prescriptions, costing about £100-£150 per month, already vastly outnumber that and are rising. Health Secretary Wes Streeting wants a faster rollout and more widespread use of the drugs but patients must also receive regular check-ups and lifestyle help. Officials are investigating whether they can dish them out through pharmacies or the NHS app to take a load off GPs. Professor Jason Halford, of the European Association for the Study of Obesity, said: 'These drugs have the potential to help millions. 'If the government and NHS are serious about prevention they need to reconsider their position on the speed of the rollout of these drugs.' Professor John Deanfield, a heart doctor at University College London, added: 'These drugs provide a real opportunity to delay many diseases of ageing all at the same time and potentially transform society. 'I hope it won't take 10 years to do something that is so needed.' What if my GP says no? MANY people are expected to miss out and some surgeries are already pouring cold water on patients' hopes. Fairhill Medical Practice in Kingston upon Thames said: 'Once we are able to prescribe weight loss injections they will be offered to those with the highest medical need only, which may mean that a lot of patients will be disappointed.' Millions who meet the prescription criteria will simply have to be denied the drugs because doctors are so busy. On top of everything else England's 6,300 doctors' surgeries have to deal with, they do not have the capacity to offer the necessary long-term supervision for millions more people at once. Experts reckon private prescriptions will rocket even more as frustrated patients give up waiting. If you are eligible but your GP denies you a prescription, you may be able to ask for a referral to specialist weight management services. Known as tier 2 and tier 3 weight management services, they may prescribe the jabs after other weight loss attempts. Many people are expected to find it easier to go private, with the injections widely available from high street pharmacies like Boots, Superdrug, and even Asda. Olivier Picard, of the National Pharmacy Association, said: 'NHS provision won't meet demand straight away, so we fully expect that many people will continue seeking it privately.' Advice for people buying them privately BUYING the drugs online might seem like the faster fix – but buyer beware. Slimming success stories are everywhere but so, too, are tales of horror. Many patients have been duped by dodgy sellers, suffered severe side effects or even died after taking jabs they bought online. Bargain prices, easy tick-box applications, or prescriptions with no follow-up, should all be red flags to online shoppers. Many pharmacies have been rapped for giving them away to people who do not meet the obesity criteria, potentially putting their health at risk. Dose strength is partly based on size and pretending you are fatter than you are could mean you end up with a medication too strong for your body, raising the risk of serious side effects. The most common side effects from the injections include feeling sick, vomiting, diarrhoea or other gut troubles. If not treated properly people can suffer more serious impacts like dehydration, gallstones, pancreatitis or allergic reactions – and more than 100 deaths in the UK have so far been linked to the jabs. The General Pharmaceutical Council issued new rules in February to say that all pharmacies must verify a patient's height and weight, and conduct at least a video call – if not face-to-face appointment – before prescribing weight loss injections. Dr Emily Pegg, associate vice president at Lilly, which makes Mounjaro, said: 'This is still a prescription-only medicine, should only be prescribed by a registered healthcare professional and needs to be dispensed by a registered pharmacy. 'It is not something that people should be able to buy by just going out and going on to a social media site and clicking a button and it gets delivered to them. 'That is not appropriate and is probably illegal. 'Patient safety is a high priority.' Everything you need to know about fat jabs Weight loss jabs are all the rage as studies and patient stories reveal they help people shed flab at almost unbelievable rates, as well as appearing to reduce the risk of serious diseases. Wegovy – a modified version of type 2 diabetes drug Ozempic – and Mounjaro are the leading weight loss injections used in the UK. Wegovy, real name semaglutide, has been used on the NHS for years while Mounjaro (tirzepatide) is a newer and more powerful addition to the market. Mounjaro accounts for most private prescriptions for weight loss and is set to join Wegovy as an NHS staple this year. How do they work? The jabs work by suppressing your appetite, making you eat less so your body burns fat for energy instead and you lose weight. They do this my mimicking a hormone called GLP-1, which signals to the brain when the stomach is full, so the drugs are officially called GLP-1 receptor agonists. They slow down digestion and increase insulin production, lowering blood sugar, which is why they were first developed to treat type 2 diabetes in which patients' sugar levels are too high. Can I get them? NHS prescriptions of weight loss drugs, mainly Wegovy and an older version called Saxenda (chemical name liraglutide), are controlled through specialist weight loss clinics. Typically a patient will have to have a body mass index (BMI) of 30 or higher, classifying them as medically obese, and also have a weight-related health condition such as high blood pressure. GPs generally do not prescribe the drugs for weight loss. Private prescribers offer the jabs, most commonly Mounjaro, to anyone who is obese (BMI of 30+) or overweight (BMI 25-30) with a weight-related health risk. Private pharmacies have been rapped for handing them out too easily and video calls or face-to-face appointments are now mandatory to check a patient is being truthful about their size and health. Are there any risks? Yes – side effects are common but most are relatively mild. Around half of people taking the drug experience gut issues, including sickness, bloating, acid reflux, constipation and diarrhoea. Dr Sarah Jarvis, GP and clinical consultant at said: 'One of the more uncommon side effects is severe acute pancreatitis, which is extremely painful and happens to one in 500 people.' Other uncommon side effects include altered taste, kidney problems, allergic reactions, gallbladder problems and hypoglycemia. Evidence has so far been inconclusive about whether the injections are damaging to patients' mental health. Figures obtained by The Sun show that, up to January 2025, 85 patient deaths in the UK were suspected to be linked to the medicines. Future of fat jabs WHILE the Mounjaro rollout is expected to kick off with a whimper and not a bang, it is hoped it will mark the beginning of a new era in weight loss medicine. Brits have been getting gradually fatter for decades and no medication or government policy has managed to beat the bulge. The drugs appear super-effective, reasonably priced and relatively safe, and could help millions slim down after failed diets. They are expected to reduce the risks of type 2 diabetes, cancer and dementia. And studies increasingly show they improve health in other ways on top of weight loss, too, reducing the risk of heart attacks and strokes. NHS medical director, Professor Sir Stephen Powis, believes they could one day be as transformative as cholesterol-lowering statins, which have slashed heart attacks since they were rolled out decades ago. Prof Powis said: 'I think over time it's highly likely that these drugs will become more widespread. 'I think there will be a combination of increased evidence of positive outcomes and costs dropping, and we will learn better how to deploy them. 'This is very exciting – we're in the foothills of learning how to use them.'
